Systemic drug administration in tumor treatment is hindered by biological barriers, leading to side effects. This study develops an intelligent drug (iMSCEndostatin) using mesenchymal stem cells (MSCs) programmed to selectively deploy endostatin at the tumor site. This 'defensive targeting' strategy prevents drug accumulation in healthy tissues, unlike traditional aggressive targeting approaches. Using Her2+ tumors, iMSCEndostatin demonstrates autonomous tumor cell recognition and precise endostatin delivery, minimizing off-target toxicity.
Publisher
Cell Death and Disease
Published On
Aug 28, 2024
Authors
Yuliang Sun, Yilin Lu, Xinze Li, Yanan He, Then Kong Yong, Cheong Soon Keng, Badrul Yahaya, Yanli Liu, Juntang Lin
Tags
iMSCEndostatin
mesenchymal stem cells
tumor treatment
endostatin delivery
off-target toxicity
cancer therapy
Related Publications
Explore these studies to deepen your understanding of the subject.